SymBio Pharmaceuticals (4582) - Looking forward to Treakisym Phase III data

06:47 EDT 17 Apr 2019 | Edison Investment Research

Edison Investment Research - Pharmaceuticals & healthcare - SymBio Pharmaceuticals: Treakisym continues to generate double-digit sales growth, although 2018 sales were below our expectations. A temporary dip in revenue is expected in 2020 as inventory held by Eisai is wound down, ahead of SymBio establishing its own sales organisation in Japan at the end of that year. The ongoing Phase III study of Treakisym in diffuse large B-cell lymphoma (DLBCL) is on track to allow a potential filing in Q220; we estimate that the DLBCL indication could double peak sales, if approved. SymBio reaffirmed its key goal to become profitable in 2021, the first full year of Treakisym self-commercialisation. Our valuation is ¥26.8bn or ¥308/share.
ISIN: JP3383050006

Original Article: SymBio Pharmaceuticals (4582) - Looking forward to Treakisym Phase III data


More From BioPortfolio on "SymBio Pharmaceuticals (4582) - Looking forward to Treakisym Phase III data"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...